Ground breaking IONA test

Seneca EIS portfolio company Premaitha Health is on the verge of tapping into a multi-billion pound market with its ground breaking non-invasive prenatal screening test for pregnant women.

Chief executive of the Manchester-based company, Dr Stephen Little, said there was already strong demand for the newly-developed IONA test, which detects the risk of Downes Syndrome and other serious genetic diseases in unborn babies.

“We weren’t making money, but we were developing a product,” he said. “Now it’s there and available. We’re using it. Tests are getting done. This is only in the last couple of months, but it’s all happening now. Up until the back end of last year, we were effectively a development company. Now we are a sales and marketing company.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.